Teprotumumab effects on thyroid eye disease in a Japanese MRI study: comparison with intravenous glucocorticoid therapy
Authors' conclusion
TEP showed robust effectiveness in Japanese real-world patients with TED. MRI-based analyses revealed distinct effects of TEP and IVGC on orbital fat and identified inflamed extraocular muscles as treatment-responsive components.
Study context
- Population
- Japanese patients with thyroid eye disease (TED) starting teprotumumab (TEP) at Kyoto University Hospital by July 31, 2025
- Participants
- 18 vs 20
- Exposure
- Teprotumumab vs intravenous glucocorticoid therapy
- TEPn = 18
- Intravenous glucocorticoid (IVGC)n = 20reference
- Outcome
- Proptosis (Hertel exophthalmometer), TEP cohort
- Follow-up
- 24 weeks
Methodological detailssingle-centre, historical comparison cohort, MRI-based
- Single-centre
- Historical comparison cohort
- MRI-based
Main finding
As reported in the abstract
P = 0.025
Observational data: associations, not effects.
Further findings
Clinical activity score · 24 weeks of TEP
- CAS before TEP, median (IQR-type range)
- 4 (3-5) point
- CAS after 24 weeks of TEP
- 1 (0-1) point
- CAS decrease with TEP
- P < 0.001
Diplopia: reduction ≥1 point in Gorman score
- Patients with diplopia
- 15
- Reduction of ≥1 point in Gorman score
- 9 patients (60.0%)
Thyroid-stimulating antibody titers
- Titer before
- 1,180% (349-4,710)
- Titer after
- 282% (132-504)
- Decrease
- P = 0.013
MRI orbital components vs IVGC cohort
- TEP reduced both extraocular muscle and orbital fat areas
- IVGC reduced extraocular muscle area but increased orbital fat area
- Inflamed extraocular muscles on MRI were enlarged at baseline and shrank markedly after both therapies
Original publication
Teprotumumab effects on thyroid eye disease in a Japanese MRI study: comparison with intravenous glucocorticoid therapy. J Clin Endocrinol Metab. Published 25 August 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →